Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Frank M. Fabian"'
Autor:
Kanagasabai Vadivel, Anne K. Zaiss, Yogesh Kumar, Frank M. Fabian, Ayman E. A. Ismail, Mark A. Arbing, Wallace G. Buchholz, William H. Velander, S. Paul Bajaj
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 11, p 3684 (2020)
Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however,
Externí odkaz:
https://doaj.org/article/8225ff1b319d465197425cdb0dec2bd3
Autor:
Ayman E.A. Ismail, William H. Velander, Mark A. Carlson, Frank M. Fabian, Ou Wang, Yuguo Lei, Han Li, Carlos Poblete Jara, William Burgess, Licio A. Velloso, Eliana P. Araújo, Thais Paulino do Prado
Publikováno v:
Bioactive Materials, Vol 5, Iss 4, Pp 949-962 (2020)
Bioactive Materials
Bioactive Materials
Plasma fibrinogen (F1) and fibronectin (pFN) polymerize to form a fibrin clot that is both a hemostatic and provisional matrix for wound healing. About 90% of plasma F1 has a homodimeric pair of γ chains (γγF1), and 10% has a heterodimeric pair of
Autor:
Mark A. Carlson, Ayman E.A. Ismail, Wilson H. Burgess, Frank M. Fabian, Ou Wang, William H. Velander, Yuguo Lei
Publikováno v:
Process Biochemistry. 75:257-265
Human plasma fibronectin (FN) enhances fibrin polymer strength and is typically present at
Autor:
S. Paul Bajaj, Wallace G. Buchholz, Yogesh Kumar, William H. Velander, Anne K. Zaiss, Kanagasabai Vadivel, Frank M. Fabian, Ayman E.A. Ismail, Mark A. Arbing
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 11
Journal of Clinical Medicine, Vol 9, Iss 3684, p 3684 (2020)
Volume 9
Issue 11
Journal of Clinical Medicine, Vol 9, Iss 3684, p 3684 (2020)
Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., &epsilon
aminocaproic acid and tranexamic acid)
aminocaproic acid and tranexamic acid)
Publikováno v:
Analytical biochemistry. 598
We previously reported on a novel fibrin matrix having increased viscoelastic strength derived from human plasma fibronectin (pFN) and γγ′-fibrinogen (γγ′-FI). Here we use high pressure size exclusion chromatography (HPSEC) and dynamic light
Autor:
Ou Wang, Qiang Li, Yuguo Lei, Haishuang Lin, William H. Velander, Frank M. Fabian, Mark A. Carlson, Srivatsan Kidambi, Wilson H. Burgess, Ayman E.A. Ismail, Christian Elowsky
Publikováno v:
Journal of biomedical materials research. Part A. 106(12)
Mesenchymal stem cells (MSCs) have been widely studied for tissue engineering and treating diseases in laboratories, clinical trials, and clinics. Fibrin matrices are often used to culture MSCs or increase the retention of MSCs at the injection site.